Table 3.

Cost-effectiveness and ESRD lifetime incidence results of microalbuminuria screening, by race

All African AmericansAll Non-African Americans
Costs ($)QALYICER versus Usual ($)ICER versus Next Most Effective ($)ESRD Lifetime IncidenceaCosts ($)QALYICER versus Usual ($)ICER versus Next Most Effective ($)ESRD Lifetime Incidencea
Usual care148,20016.53782150,30018.01035
Universal (yr)
 10148,40016.567900079150,50018.02217,00033
 5148,50016.57111,00024,00078150,70018.02523,00054,00033
 2148,90016.57419,000113,00078151,00018.02744,000210,00033
 1149,40016.57533,000635,00078151,70018.02781,0001,571,00033
  • a Lifetime incidence of initiating ESRD care per 1000 persons.